Medical Oncology

Doç. Dr. Seray Saray

Doctor and researcher Balıkesir Atatürk Şehir Hastanesi Balıkesir
Breast Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • InstitutionBalıkesir Atatürk Şehir Hastanesisaglik.gov.trFrom source
  • Area of workBreast NeoplasmsExtracted from 5 publications · Model version —From source
  • Publications42 publicationsORCID, OpenAlexFrom source
  • ORCID0000-0001-5916-6265ORCIDFrom source
  • Last synchronised5 November 2026 07:37https://balikesirataturksehir.saglik.gov.tr/TR-677864/doktorlarimiz.html#seray-saraysaglik.gov.tr

Scientific work

Publications on Breast Neoplasms

42 publications

  1. Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15062353 PMID 41899277 Open-access full textSource: ORCID

  2. Stage 4A Lung Adenocarcinoma with Rare EGFR Exon 21 L861Q and Exon 18 G719A Co-Mutations Showing Complete PET-CT Response to Osimertinib: A Case Report

    Case Reports in Oncology, 2026

    DOI 10.1159/000551796 PMID 42257038 Open-access full textSource: ORCID

  3. Radiotherapy improves outcomes in patients with NSCLC receiving nivolumab

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-15805-w PMID 41749167 Open-access full textSource: ORCID

  4. Analysis of prognostic factors in metastatic colon cancer

    Turkish Journal of Clinics and Laboratory, 2026

    DOI 10.18663/tjcl.1803902 Open-access full textSource: ORCID

  5. Do Inflammatory Indices Predict Neoadjuvant Chemotherapy Response in Hormone Receptor-positive, HER2-negative Breast Cancer?

    Namık Kemal Tıp Dergisi, 2026

    DOI 10.4274/nkmj.galenos.2025.81594 Open-access full textSource: OpenAlex

  6. Low baseline breast TLG and axillary MTV independently predict pathological complete response in HR-positive/HER2-negative breast cancer

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-17192-8 Open-access full textSource: OpenAlex

  7. The ımpact of the novel tumor marker ındex (TMI) on survival and prognosis in metastatic gastric cancer

    American Journal of Cancer Research, 2026

    DOI 10.62347/jgid2940 Source: OpenAlex

  8. Real-life data on adjuvant trastuzumab emtansine treatment in early-stage HER2-positive breast cancer: a Turkish Oncology Group study

    Anti-Cancer Drugs, 2025

    DOI 10.1097/cad.0000000000001717 PMID 40162996 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  9. Comparison of the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of metastatic gastric cancer: a multicenter retrospective study

    Therapeutic Advances in Medical Oncology, 2025

    DOI 10.1177/17588359251368069 PMID 40900677 5 citations (Europe PMC) Open-access full textSource: OpenAlex

  10. FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG)

    Cancers, 2025

    DOI 10.3390/cancers17172730 PMID 40940827 Open-access full textSource: ORCID

View all 42 publications